The RIVM as knowledge and training centre

Size: px
Start display at page:

Download "The RIVM as knowledge and training centre"

Transcription

1 The RIVM as knowledge and training centre Belgrade, Serbia March 2012 Marit Holleman 1

2 Content: 1. Training and Technology Transfer at RIVM 2. Training on influenza vaccines 3. New courses 2

3 Training and TT at RIVM Over 100 years of experience on manufacturing of EPI vaccines in the public domain. Delivered various TT & training programs on vaccine production and QC Numerous developing country vaccine manufacturers and NRA/NCL have sent their staff to attend one of these training programs. hands-on courses where learning by doing is the driving force. Vaccine experts to complete the curriculum Partner of the WHO Global Learning Opportunities for Vaccine Quality (GLO/VQ). 3

4 Vaccinology expertise R&D and Clinical&Regulatory Research Small scale GMP production facility QC department Incl. Animal facility 4

5 Past RIVM training courses and workshops Training program Occurrences Dates DTP vaccine production 3 courses 1998, 1999, 2001 QC of DTP vaccines 6 courses , 2003 Animal husbandry for QC 4 courses 1998, 1999, 2002, 2006 QC of Hib conjugate vaccines 3 courses 2007, 2008 GMP-QA aspects of influenza vaccines 1 course 2009 Production and QC of influenza whole cell and split vaccines 6 courses Sabin IPV workshop 1 session

6 Knowledge transfer and training at RIVM means: Grantees will have access to: Technical advice Process and production technology Documentation Assays (Pre)clinical support 6

7 Technology transfer influenza Vacsera Egypt Consultancy agreement Advice on process development and QC Advice on documentation/validation IVAC VietNam Consultancy agreement Advice production process and QC Experts visits 7

8 Learning by doing 8

9 Training courses on influenza vaccines Since start of the influenza project 2008 several training courses: 2009 June : 1 week Workshop GMP/QA 2009 Dec } 2010 March : 3 week generic course influenza production and QC 2010 April 2010 May : 3 week hands-on operator course Vacsera 2010 June : 2 week hands-on operator course IVAC 2011 Feb : 3 week generic course influenza production and QC 2012 Feb : 2 week hands-on training on influenza vaccine manufacturing for whole virus and split vaccines 9

10 Recipients of influenza vaccine training and TT 2009 Croatia, Institute of Immunology Egypt, Vacsera Indonesia, Bio Farma Iran, Razi Serbia, Torlak Thailand, GPO Vietnam, IVAC 2010 Argentina, ANLIS China, SIBP China, Zejing Pharmaceuticals China, CCIBP Croatia, Inst. of Immunology Egypt, Vacsera India, Indian Immunologicals Iran, Razi Kazakhstan, RIBSP Romania, Cantacuzino Thailand, GPO Thailand, QSMI Vietnam, IVAC 2011 Mexico, Birmex Indonesia, Bio Farma Kazakhstan, RIBSP Korea, Il-Yang Canada/China, Microbix 2012 Ivac, Vietnam Vacsera, Egypt Total number of institutes: 18 Total number of trainees: 65 10

11 TT Recipients Institutes: 18 Trainees: 65 Serbia, Torlak Croatia, Inst.of Imm. Romania, Cantacuzino Kazakhstan, RIBSP Korea, Il- Yang Canada, Microbix China, SIBP, CCIBP & Zejing Pharm. Mexico, Birmex Vietnam, IVAC Iran, Razi Thailand, GPO & QSMI Argentina, ANLIS Egypt, Vacsera India, Indian Imm. Ltd Indonesia, Bio Farma 11

12 Generic training courses in influenza vaccines Three weeks duration 10 bench places Two volume Course Manual Hands-on: practicing production run Two groups: Production & Quality Control 12

13 Impression courses 13

14 Training programs under construction: TRAINING PROGRAM DESCRIPTION TARGET AUDIENCE Critical Quality Attributes for preparation of influenza vaccines Manufacturing and QC of split virus influenza vaccine Evaluate and review product quality, safety and efficacy in (pre-) clinical studies of influenza vaccines. Process validation Comparing different guidelines Tailor made hands on training National Regulatory Authorities, National Control Laboratories, QA/QP Manufacturers Assay validation How to validate an analytical method QC and R&D staff Sabin IPV vaccines QC of conjugate vaccine Hands on training on the manufacturing of Sabin IPV vaccines QC tests and data interpretation for hib vaccine Manufacturers Manufacturers, NRA/NCL From vaccine concept to clinical study Insight in complete route of vaccine development Start up biotechnology companies and academic research groups 14

15 THANK YOU 15

Progress under GAP Pillar 2 "Increase Production Capacity" Contribution of the WHO Technology Transfer Programme. Martin Friede

Progress under GAP Pillar 2 Increase Production Capacity Contribution of the WHO Technology Transfer Programme. Martin Friede Progress under GAP Pillar 2 "Increase Production Capacity" Contribution of the WHO Technology Transfer Programme Martin Friede Global influenza vaccine production capacity since 2006 Cantacuzino Romania

More information

NVI Experience and Concept of Central Technology Hub

NVI Experience and Concept of Central Technology Hub NVI Experience and Concept of Central Technology Hub Jan Hendriks Netherlands Vaccine Institute (NVI) MSF/Oxfam Consultation improving access and stimulating vaccine development for use in resource pour

More information

Jan Hendriks & Claire Boog Netherlands Vaccine Institute (NVI)

Jan Hendriks & Claire Boog Netherlands Vaccine Institute (NVI) Influenza Technology Hub a WHO Vaccinology Centre of Excellence Bilthoven, the Netherlands WHO Technology Transfer Workshop 30 November-1 December 2010 Jan Hendriks & Claire Boog Netherlands Vaccine Institute

More information

Biomanufacturing Training and Education Center (BTEC) s International Influenza Vaccine Manufacturing Training Program

Biomanufacturing Training and Education Center (BTEC) s International Influenza Vaccine Manufacturing Training Program Biomanufacturing Training and Education Center (BTEC) s International Influenza Vaccine Manufacturing Training Program 5 th Meeting with International Partners on Prospects for Influenza Vaccine Manufacturing

More information

Approaches to Pandemic Influenza Vaccine Preparedness

Approaches to Pandemic Influenza Vaccine Preparedness United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Approaches to Pandemic Influenza Vaccine Preparedness Julie Schafer, MPH, MS Influenza

More information

Outline. World Health Organization 14 July, Strengthening for capacity to regulate influenza vaccines

Outline. World Health Organization 14 July, Strengthening for capacity to regulate influenza vaccines Strengthening for capacity to regulate influenza vaccines Outline WHO reorganization and Regulatory Systems Strengthening (RSS) Team WHO Regulatory Systems Strengthening Department of Essential Medicines

More information

Influenza Vaccine Innovation

Influenza Vaccine Innovation United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Influenza Vaccine Innovation New Vaccines Approved and on the Way Rick A. Bright, Ph.D.

More information

How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin

How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low

More information

Vaccine Development in the Developing World; past, present and future: SEAR Perspective

Vaccine Development in the Developing World; past, present and future: SEAR Perspective Speech by Dr Samlee Plianbangchang Regional Director, WHO South-East Asia Vaccine Development in the Developing World; past, present and future: SEAR Perspective 15 June 2010 Bangkok, Thailand Vaccine

More information

Towards a Sustainable Global Infrastructure for Medical Countermeasures

Towards a Sustainable Global Infrastructure for Medical Countermeasures Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from

More information

Current needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution

Current needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution Current needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution by DR.SURESH S. JADHAV Executive Director Serum Institute of India Ltd/Pune & President

More information

Meeting with international partners on influenza vaccine production technology transfer to developing countries

Meeting with international partners on influenza vaccine production technology transfer to developing countries WHO/IVB/10.10 ORIGINAL: ENGLISH Meeting with international partners on influenza vaccine production technology transfer to developing countries 5-6 May 2010, Nha Trang, Viet Nam Immunization, Vaccines

More information

V3P: Region Fact Sheet

V3P: Region Fact Sheet V3P: Region Fact Sheet Highlights The 1 region market is 4% of the global market in volume and 5% in value. The regional vaccine procurement habits are different from the rest of the world in several ways,

More information

V3P: Region Fact Sheet

V3P: Region Fact Sheet V3P: Region Fact Sheet Highlights The 1 region market is 6% of the world market in volume and 6% in value. The regional vaccine procurement habits are different from the rest of the world in several ways,

More information

Prospective Models of Vaccine Security Collaborations in Research and Development

Prospective Models of Vaccine Security Collaborations in Research and Development Prospective Models of Vaccine Security Collaborations in Research and Development Georges Thiry, PhD IVI (International Vaccine Institute) Phuket, Oct 01, 2014 Content R&D Examples of collaborations from

More information

Technology Transfer from the Perspective of IFPMA vaccine members

Technology Transfer from the Perspective of IFPMA vaccine members Technology Transfer from the Perspective of IFPMA vaccine members WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Michael Watson (Sanofi Pasteur) Chair of IFPMA Biologicals

More information

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business

More information

V3P: Region Fact Sheet

V3P: Region Fact Sheet V3P: Region Fact Sheet Highlights The 1 region market is 15% of the global market in volume and 63% in value. The regional vaccine procurement habits are different from the rest of the world in several

More information

The Vaccine Formulation Laboratory

The Vaccine Formulation Laboratory FIFTH MEETING WITH INTERNATIONAL PARTNERS ON PROSPECTS FOR INFLUENZA VACCINE TECHNOLOGY TRANSFER TO DEVELOPING COUNTRY VACCINE MANUFACTURERS The Vaccine Formulation Laboratory Adjuvant Hub & Training Center

More information

Current Trends in ODS Production and Supply

Current Trends in ODS Production and Supply 6 5 4 3 2 1 1995 1997 1999 21 23 25 27 29 Current Trends in ODS Production and Supply Erik Pedersen Tenth Annual Financial Agents Workshop The World Bank Washington, D.C. June 27 to June 28, 26 Apparent

More information

Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva

Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva Pandemic H1N1 2010 Dr. Maria Neira Global Influenza Programme WHO, Geneva WHO Role during pandemic (H1N1) 2009 Under the International Health Regulations (2005) Detect event (notification by Member States

More information

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries.

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities

More information

Intellectual Property Rights & Vaccines in Developing Countries

Intellectual Property Rights & Vaccines in Developing Countries Intellectual Property Rights & Vaccines in Developing Countries by Dr. S.S.Jadhav President DCVMN Developing Country Vaccine Manufacturers Network DCVMN Formed in November 2000. 7 members steering committee.

More information

WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES

WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES Immunization and vaccine development in the last decade Since the Millennium Summit in 2000, immunization substantial international

More information

DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014.

DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. DCVMN AND VACCINE SECURITY IN ASEAN REGION ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. Phuket - Thailand Developing Countries Vaccine Manufacturers Network (DCVMN)

More information

Quality assurance for essential medicines and health products: moving towards an harmonized approach

Quality assurance for essential medicines and health products: moving towards an harmonized approach Quality assurance for essential medicines and health products: moving towards an harmonized approach Prequalification of vaccines David Wood QSS/EMP/WHO 12 December 2012 A growing portion of vaccines procured

More information

BIOFARMA EXPERIENCE WITH ASEAN CTD. Novotel, Shanghai Day 4, Thursday 22 nd March 2018, CTD session

BIOFARMA EXPERIENCE WITH ASEAN CTD. Novotel, Shanghai Day 4, Thursday 22 nd March 2018, CTD session BIOFARMA EXPERIENCE WITH ASEAN CTD Novotel, Shanghai Day 4, Thursday 22 nd March 2018, CTD session ASEAN ASEAN CTD (ACTD) Established in Jakarta (ASEAN Secretariat), December 2016 Guideline of the agreed

More information

Establishing human vaccine manufacturing in Southern Africa

Establishing human vaccine manufacturing in Southern Africa Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Establishing human vaccine manufacturing in Southern Africa Morena Makhoana The Biovac Institue

More information

Development of Vaccine Security at the Regional Level

Development of Vaccine Security at the Regional Level Workshop among ASEAN countries on Opportunities for Regional Vaccine Security September 30 to October 3, 2014, Cape Panwa, Phuket, Thailand Development of Vaccine Security at the Regional Level Stephane

More information

New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007

New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007 New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007 Session IV Influenza Pandemic Preparedness Dr Paul R Gully Health Security and Environment, Geneva Avian Influenza

More information

Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006

Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006 Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine use from high to low income countries since 2006 Dr. Michael Watson, sanofi-pasteur on behalf of WHO GAP

More information

Pentabio Vaccine (DTP-HB-Hib)

Pentabio Vaccine (DTP-HB-Hib) SUMMARY OF PRODUCT CHARACTERISTICS Product Name Pharmaceutical Form Strength Presentation : Pentabio : Suspension for injection : 1, 5 and 10 doses : Box of 10 vials @ 0.5 ml Box of 10 vials @ 2.5 ml Box

More information

Polio Eradication and Surveillance. December

Polio Eradication and Surveillance. December Polio Eradication and Surveillance December 2017 1 Acute Flaccid Paralysis (AFP) surveillance for polio eradication: >100,000 reported AFP per year December 2017 2 Global Laboratory Network for Polio Eradication

More information

Heat and Freeze Sensitivity of Vaccines

Heat and Freeze Sensitivity of Vaccines Heat and Freeze Sensitivity of Vaccines DCVMN Workshop "Vaccine quality management systems for manufacturing excellence" Michael Rush, MBA Executive Director - Global Health Policy October 24-25, 2013

More information

Evaluating the acceptability of vaccine and vaccination programmes: an individual and public health perspective

Evaluating the acceptability of vaccine and vaccination programmes: an individual and public health perspective The regulatory process Evaluating the acceptability of vaccine and vaccination programmes: an individual and public health perspective Annecy, Les Pensières July 7-9, 2008 Dr. Nora Dellepiane, Scientist

More information

Global Measles and Rubella Update. April 2018

Global Measles and Rubella Update. April 2018 Global Measles and Rubella Update April 218 Measles Number of Reported Measles by WHO Regions 218 Region Member States* Suspected cases Measles cases Clin Epi Lab Jan Feb Mar Apr May Jun Jul Aug Sep Oct

More information

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

Recommended composition of influenza virus vaccines for use in the 2007 influenza season Recommended composition of influenza virus vaccines for use in the 2007 influenza season September 2006 This recommendation relates to the composition of vaccines for the forthcoming winter in the southern

More information

Adjuvant technology transfer hub

Adjuvant technology transfer hub Adjuvant technology transfer hub An example of transferring «enabling technologies» Nicolas Collin, DVM, PhD Vaccine Formulation Laboratory, University of Lausanne WH Collaborating Centre Workshop on Technology

More information

Press Room M0E: Vienna International Centre, Vienna, Austria MONDAY, 11 FEBRUARY 2013 (DAY 1)

Press Room M0E: Vienna International Centre, Vienna, Austria MONDAY, 11 FEBRUARY 2013 (DAY 1) Technical Meeting on Topical Issues on Infrastructure Development: Nuclear Power Project Development in Emerging Nuclear Power States 11-14 February 2013 Press Room M0E: Vienna International Centre, Vienna,

More information

Guidance for Travelers on Temporary Work Assignment Abroad

Guidance for Travelers on Temporary Work Assignment Abroad infected person to immediately seek medical care but, prior to arrival, notify their healthcare provider that they may have been exposed to AI. For more information about avian influenza, see www.cdc.gov/flu/avian/facts.htm,

More information

Pneumococcal Symposium

Pneumococcal Symposium 3 rd Regional Pneumococcal Symposium 13-14 14 February 2008 Istanbul, Turkey Dr. Akira Homma Bio-Manguinhos, Fiocruz DCVMN Developing Countries Vaccine Manufacturers Network -DCVMN- Formed in 2000, Bandung,

More information

Global Measles and Rubella Update October 2018

Global Measles and Rubella Update October 2018 Global Measles and Rubella Update October 218 Measles Number of Reported Measles Cases by WHO Regions 218 Region Member States* Suspected cases Measles cases Clin Epi Lab Jan Feb Mar Apr May Jun Jul Aug

More information

Global Measles and Rubella Update November 2018

Global Measles and Rubella Update November 2018 Global Measles and Rubella Update November 218 Measles Number of Reported Measles by WHO Regions 218 Region Member States* Suspected cases Measles cases Clin Epi Lab Jan Feb Mar Apr May Jun Jul Aug Sep

More information

Global EHS Resource Center

Global EHS Resource Center Global EHS Resource Center Understand environmental and workplace safety requirements that affect your global operations. 800.372.1033 bna.com/gelw Global EHS Resource Center This comprehensive research

More information

ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES

ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES 1 Relationship between research funding and burden of disease Source: Global Forum for Health Research Monitoring Financial Flows for Health Research

More information

Stanley A. Plotkin ADVAC /10/2010 2:35 PM

Stanley A. Plotkin ADVAC /10/2010 2:35 PM How and dwh Why Vaccines are Made Stanley A. Plotkin ADVAC 1 2010 5/10/2010 2:35 PM 1 Vaccines 1. History of vaccination 2. The vaccine industry 3. Why vaccines are developed 4. The current problems of

More information

Food Literacy and Skill Development: Community & Intensive Program

Food Literacy and Skill Development: Community & Intensive Program Food Literacy and Skill Development: & Program 2011-2012 Foodbank WA Report July 2012 Christina Davies Research and Evaluation Consultant christina.davies@westnet.com.au INTRODUCTION The aim of the Food

More information

UNICEF IPV Tender: Demand Forecast UNICEF Bidder s Conference WHO, Geneva 11 October 2013

UNICEF IPV Tender: Demand Forecast UNICEF Bidder s Conference WHO, Geneva 11 October 2013 UNICEF IPV Tender: Demand Forecast UNICEF Bidder s Conference WHO, Geneva 11 October 2013 1 Overview of forecast To inform financial resource requirements, Supply and Procurement Roadmap development and

More information

Current Situation on Avian Influenza and the pandemic threat

Current Situation on Avian Influenza and the pandemic threat Vaccine-preventable diseases and Immunization, Communicable Diseases Surveillance and Response Current Situation on Avian Influenza and the pandemic threat IVth Joint EC/ECDC/WHO Workshop on Pandemic Influenza

More information

Global Efforts to Understand Influenza Disease Burden

Global Efforts to Understand Influenza Disease Burden National Center for Immunization & Respiratory Diseases Global Efforts to Understand Influenza Disease Burden A. Danielle Iuliano, PhD, MPH Influenza Division Centers for Disease Control and Prevention

More information

Dr Laszlo Palkonyay World Health Organization

Dr Laszlo Palkonyay World Health Organization International Proficiency Study of the Single Radial Immuno Diffusion Test (SRID) for Influenza Vaccine Manufacturers and Regulators from Developing Countries Dr Laszlo Palkonyay World Health Organization

More information

Regional Overview of the implementation of National Control Strategies for Avian Influenza. Summary review of questionnaire OIE RRAP

Regional Overview of the implementation of National Control Strategies for Avian Influenza. Summary review of questionnaire OIE RRAP Regional Overview of the implementation of National Control Strategies for Avian Influenza Summary review of questionnaire OIE RRAP The OIE Questionnaire on Influenza A surveillance in animals in the Asia

More information

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017 EU Market Situation for Poultry Committee for the Common Organisation of the Agricultural Markets 2 April 217 -9.% -11.% -5.% -.1% -.7% -2.2% 3.% 1.7% 1.2%.8%.6%.%.%.% 7.9% 7.% 6.4% 6.2% 6.% 5.5% 5.3%

More information

WHO Recommendations and Guidelines for the Prevention of Perinatal Hepatitis B and Use of Hepatitis B Vaccines

WHO Recommendations and Guidelines for the Prevention of Perinatal Hepatitis B and Use of Hepatitis B Vaccines WHO Recommendations and Guidelines for the Prevention of Perinatal Hepatitis B and Use of Hepatitis B Vaccines Steven Wiersma,, Medical Officer WHO/EPI EPI,, Geneva March, 2006 Epidemiology Strategy WHO

More information

OIE Situation Report for Avian Influenza

OIE Situation Report for Avian Influenza OIE Situation Report for Avian Influenza Latest update: 24/04/2017 This report presents an overview of current disease events reported to the OIE by its Members. The objective is to describe what is happening

More information

Vaccine Production and Regulation

Vaccine Production and Regulation Vaccine Production and Regulation Dr Houda LANGAR Essential Vaccines and Biologicals Policy Department of Health Systems & Services Development Capacity Development Workshop on Health System Development

More information

Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing

Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Nathalie Charland, PhD GHSI Workshop on Public Health Emergency Medical Countermeasures

More information

Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China. Gu Hong Ministry of Agriculture of P. R. China

Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China. Gu Hong Ministry of Agriculture of P. R. China Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China Gu Hong Ministry of Agriculture of P. R. China AI -- common challenge to the all countries Global cooperation in control

More information

Summaries of Complementary Presentations on Agenda Item:

Summaries of Complementary Presentations on Agenda Item: Summaries of Complementary Presentations on Agenda Item: WHO s Role in Supporting Emerging Vaccine Manufacturers To inform the SAGE discussion on this agenda item, four presentations have been solicited

More information

Avian Influenza (AI) National & International Update

Avian Influenza (AI) National & International Update Avian Influenza (AI) National & International Update T.J. Myers, F. Hegngi, A. Rhorer, P. Klein, T. Duvernoy & M. David USDA, APHIS, Veterinary Services Delmarva Breeder, Hatchery & Grow Out Conference

More information

Strengthening Veterinary Services in Asia

Strengthening Veterinary Services in Asia Strengthening Veterinary Services in Asia 4 th Steering Committee Highly Pathogenic Emerging and Re-Emerging Diseases (HPED) Programme Session 3 Progress on the OIE component Tokyo (Japan) 16 July 2013

More information

Report of the Fifth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine

Report of the Fifth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Report of the Fifth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers Belgrade, Serbia, 27-28 March 2012 WHO Library

More information

Regional Capacity Development and Networking Program to Improve TADs Surveillance and Control

Regional Capacity Development and Networking Program to Improve TADs Surveillance and Control Regional Capacity Development and Networking Program to Improve TADs Surveillance and Control The 7 th FAO/OIE Regional Steering Committee Meeting on GF-TADs for Asia and the Pacific 17-18 July 2013 Outline

More information

Institutional Profile I

Institutional Profile I Institutional Profile Vietnam This institution is a Private company research laboratory. According to OECD s FRASCATI Manual 1, it is a: Higher Education Institution As a possible partner in international

More information

Curriculum Vitae: David Richard BUCKLEY (Rev a)

Curriculum Vitae: David Richard BUCKLEY (Rev a) A190507 David Richard Buckley NZCS, BSc, MASM, FQSA David Buckley & Associates Pty Ltd ABN 69103221 129 7 Catani Place, Monash, ACT 2904, www.navigategmp.com E-mail: david.buckley@navigategmp.com AUSTRALIA,

More information

Short Range Outlook for Steel Demand Autumn OECD Steel Committee, Paris, 10 December Short Range Outlook overview

Short Range Outlook for Steel Demand Autumn OECD Steel Committee, Paris, 10 December Short Range Outlook overview Short Range Outlook for Steel Demand Autumn 29 OECD Steel Committee, Paris, 1 December 29 Content Short Range Outlook overview Background of the Forecast Regional overviews Conclusion 2 1 Short Range Outlook

More information

UNICEF s perspective. WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012

UNICEF s perspective. WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012 UNICEF s perspective WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012 UNICEF procures immunization supplies on behalf of around 100 countries

More information

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop

More information

Safety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist

Safety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist Safety monitoring of vaccines Jeremy Labadie MD vaccine safety specialist vaccines are special immunization programmes pharmacovigilance & vaccines vaccines & AEFI causality assessment of AEFI UMC and

More information

THE CARE WE PROMISE FACTS AND FIGURES 2017

THE CARE WE PROMISE FACTS AND FIGURES 2017 THE CARE WE PROMISE FACTS AND FIGURES 2017 2 SOS CHILDREN S VILLAGES INTERNATIONAL WHERE WE WORK Facts and Figures 2017 205 58 79 families and transit 31 Foster homes 162 8 3 173 214 2 115 159 136 148

More information

Summary and Recommendations - APEC Dialogue on Avian Influenza Risks in the Live Bird Market System (LBMS)

Summary and Recommendations - APEC Dialogue on Avian Influenza Risks in the Live Bird Market System (LBMS) 2008/ATCWG12/031 Agenda Item: XII Summary and Recommendations - APEC Dialogue on Avian Influenza Risks in the Live Bird Market System (LBMS) Purpose: Information Submitted by: United States 12 th Agricultural

More information

Last mile vaccine distribution to rural health centres. Faheem Merchant

Last mile vaccine distribution to rural health centres. Faheem Merchant Last mile vaccine distribution to rural health centres Faheem Merchant New Global Immunization Goals 2000 - Millennium Development Goal # 4 Reduce under 5 child mortality by 2/3 between 1990 and 2015.

More information

Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing. Washington, DC January 14-16, Agenda.

Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing. Washington, DC January 14-16, Agenda. Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Washington, DC January 14-16, 2013 Agenda January 14, 2013 7:45 am 5:00 pm Registration And Information 8:45 am 9:00 am Opening

More information

H5N1 avian influenza: timeline

H5N1 avian influenza: timeline H5N1 avian influenza: timeline 28 October 2005 Previous events in Asia 1996 Highly pathogenic H5N1 virus is isolated from a farmed goose in Guangdong Province, China. 1997 Outbreaks of highly pathogenic

More information

Global update on temperature monitoring

Global update on temperature monitoring Global update on temperature monitoring Why bother about temperature monitoring Objectives of the immunization supply chain Impacts of temperature excursions If undetected If detected Availability of vaccines

More information

Programme update. Prequalification of Vaccines

Programme update. Prequalification of Vaccines Programme update Prequalification of Vaccines UN Prequalification of Medicines, Diagnostics and Vaccines 6th Consultative Stakeholder Meeting 4 April 2011 David Wood, WHO/IVB/QSS Outline Good news - A

More information

Main developments in past 24 hours

Main developments in past 24 hours ECDC DAILY UPDATE Pandemic (H1N1) 2009 Update 02 October 2009, 09:00 hours CEST Main developments in past 24 hours Weekly Influenza Surveillance Overview to be published today; Media highlights and Eurosurveillance

More information

7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift

7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift People 60 Years and Older ( in Millions) 7/30/2017 One World Medical Physics: Challenges and Opportunities in Cancer Care Jatinder R Palta PhD, FAAPM, FASTRO, FACR Virginia Commonwealth University, and

More information

Childhood Vaccination and Immunisation

Childhood Vaccination and Immunisation DIRECTORATE GENERAL FOR INTERNAL POLICIES POLICY DEPARTMENT A: ECONOMIC AND SCIENTIFIC POLICY WORKSHOP Childhood Vaccination and Immunisation Brussels, 19 June 2013 MEETING DOCUMENT Policy Department A:

More information

Paradigm shift: from dependency to country ownership Seth Berkley, MD Chief Executive Officer of the GAVI Alliance

Paradigm shift: from dependency to country ownership Seth Berkley, MD Chief Executive Officer of the GAVI Alliance Paradigm shift: from dependency to country ownership Seth Berkley, MD Chief Executive Officer of the GAVI Alliance Sabin 20 th Anniversary Scientific Forum 25 April 2014 The GAVI Alliance: a public-private

More information

Proposal for a Workshop

Proposal for a Workshop Proposal for a Workshop Pre-vaccination screening for the use of dengue vaccines with differential performance dependent on serostatus: rapid diagnostic tests and implementation strategies Background:

More information

The Crisis in. Vaccine Development

The Crisis in. Vaccine Development The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.

More information

THE ROLE OF DISEASE BURDEN IN THE DECISION MAKING PROCESS: THE HIB VACCINE EXPERIENCE. Brad Gessner, MD Agence de Médecine Preventive

THE ROLE OF DISEASE BURDEN IN THE DECISION MAKING PROCESS: THE HIB VACCINE EXPERIENCE. Brad Gessner, MD Agence de Médecine Preventive THE ROLE OF DISEASE BURDEN IN THE DECISION MAKING PROCESS: THE HIB VACCINE EXPERIENCE Brad Gessner, MD Agence de Médecine Preventive INDUSTRIALIZED COUNTRIES Meningitis incidence per 1 0 0 K per year 1970s:

More information

COMBINATION VACCINES: HOW AND WHY? LESSONS LEARNED.

COMBINATION VACCINES: HOW AND WHY? LESSONS LEARNED. COMBINATION VACCINES: HOW AND WHY? LESSONS LEARNED. Global Vaccine and Immunization Research Forum Johannesburg, March 16, 2016 Michel De Wilde, MDWConsultant, LLC STRONG RATIONALE EXISTS FOR COMBINATION

More information

OFFLU AVIAN INFLUENZA REPORT

OFFLU AVIAN INFLUENZA REPORT OFFLU AVIAN INFLUENZA REPORT Avian Influenza Events in Animals for the period February to September 2017 Scope In this document we present a summary of H5, H7, and H9 avian influenza events that occurred

More information

Overview of the ProVac Initiative

Overview of the ProVac Initiative Overview of the ProVac Initiative Updated Dec. 2017 Goal of the ProVac Initiative Strengthen evidence-based decision making on immunization to sustain and further the public health impact of immunization

More information

Tendering to support new vaccine introduction in Middle Income Countries. UNICEF Supply Division Presentation to Partners 28 November 2012

Tendering to support new vaccine introduction in Middle Income Countries. UNICEF Supply Division Presentation to Partners 28 November 2012 Tendering to support new vaccine introduction in Middle Income Countries UNICEF Supply Division Presentation to Partners 28 November 2012 Tendering to Support New Vaccine Introduction in Middle Income

More information

Ready for a CRO That Values Performance Over Promises? CHALLENGE. At Clinipace, it s personal.

Ready for a CRO That Values Performance Over Promises? CHALLENGE. At Clinipace, it s personal. Ready for a CRO That Values Performance Over Promises? CHALLENGE At Clinipace, it s personal. Who We Are At Clinipace, It s Personal. We Will PROVE IT. With us, you get the A team. We deliver a level of

More information

Sperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ

Sperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ CHAPTER 8: Donation Although there has been a reduction in the use of donor sperm because of ICSI and the impact of the removal of anonymity in some countries (1), sperm donation is still used and has

More information

Outline. Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs. Immunization Landscape ADVAC 2013

Outline. Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs. Immunization Landscape ADVAC 2013 Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs ADVAC 2013 Dr. Suresh Jadhav Executive Director Serum Institute of Limited Maharashtra,, 411028 ssj@seruminstitute.com France,

More information

USAID Progress: The U.S. National Vaccine Plan of 1994

USAID Progress: The U.S. National Vaccine Plan of 1994 USAID Progress: The U.S. National Vaccine Plan of 1994 Ellyn Ogden Neal Brandes Angela Weaver Washington DC March 3, 2008 Objective 1.1/1.5 (New Vaccines) Support to GAVI for introduction of new vaccines

More information

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination.

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination. Requirements for new trials to examine offtarget effects of vaccination Workshop on: Off-target (heterologous/non-specific) effects of vaccination Les Pensieres Jun 8-10, 2015 PEM Fine London School of

More information

Total population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093

Total population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093 DPR Korea 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering -5. A standing national technical advisory group on immunization (NTAGI) with formal

More information

Cooperation between EU and China on Animal Infectious Diseases and Zoonoses

Cooperation between EU and China on Animal Infectious Diseases and Zoonoses EU-China experts seminar on developing a joint initiative for cooperation in research and innovation on food, agriculture and biotechnologies (FAB), Beijing, 10-11 October, 2013 Cooperation between EU

More information

Assessment of Influenza Vaccine Production Compatibilities

Assessment of Influenza Vaccine Production Compatibilities United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza

More information

OIE s initiative on HPAI control

OIE s initiative on HPAI control Current global situation on HPAI and OIE s initiative on HPAI control The 5 th OIE Regional Meeting on Strengthening e g Animal Health Information Networking for HPAI control and prevention in Asia Hanoi,

More information

Add value to your life and environment! DAEHO

Add value to your life and environment! DAEHO History NOV, 1986 DEC, 2001 DEC, 2005 APR, 2006 NOV, 2007 NOV, 2007 May, 2014 Establishment Achieved ISO 9001 Quality Certification system GMP was certificated by Korea government Established Central Research

More information

Review of Avian Influenza A(H5N1) for WHO SAGE

Review of Avian Influenza A(H5N1) for WHO SAGE Review of Avian Influenza A(H5N1) for WHO SAGE SAGE Geneva November 2013 Joseph Bresee, MD Epidemiology and Prevention Branch Influenza Division National Center for Immunization and Respiratory Diseases

More information

Vaccine Technologies and Global Markets

Vaccine Technologies and Global Markets A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious

More information

Protecting people against known and emerging infectious diseases globally

Protecting people against known and emerging infectious diseases globally Protecting people against known and emerging infectious diseases globally 18 October 2017 SAGE Geneva By Mahima Datla President, DCVMN 1 Agenda Introduction to DCVMN DCVMN s contributions Suggested areas

More information